• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacoepidemiology and drug safety >Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety.
【24h】

Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety.

机译：在药物安全的处方事件监视研究中，医生对未回复原因进行邮政调查的结果。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: A Prescription Event Monitoring (PEM) study was carried out by the Drug Safety Research Unit (DSRU) to monitor the safety of irbesartan, an angiotensin II antagonist, immediately after launch in the United Kingdom in September 1997. The DSRU 'green form' questionnaire response rate was lower than expected. The manufacturer was conducting a concurrent postmarketing surveillance study. The aim of this cross-sectional study, was to identify reasons for non-response by general practitioners in England. METHODS: In PEM, questionnaires are posted to the prescribing general practitioner approximately 6 months after the date of the first prescription for each patient, requesting details of clinical events recorded in the patients' notes since starting treatment. Those that failed to respond were sent a second questionnaire, including tick box questions to elucidate reasons for non-response. RESULTS: A total of 21.3% (3088/14502) second send forms were returned. There were 1747 tick box responses. The most common reason specified for non-response was 'I was too busy' (31.2%) followed by 'no payment included' (13.4%). Participation in another study accounted for only 3.4%. CONCLUSIONS: The concurrent postmarketing surveillance study was not a significant factor. The general practitioner's workload appeared to have a far larger impact. While research remains a non-core activity and receives no payment, participation is likely to fall. Researchers need to find means of benefiting the general practitioner if participation is to continue.
机译：目的：药物安全研究组（DSRU）进行了处方事件监测（PEM）研究，以监测血管紧张素II拮抗剂厄贝沙坦的安全性，该药物于1997年9月在英国上市后立即被使用。问卷答复率低于预期。制造商正在同时进行售后监视研究。这项横断面研究的目的是确定英格兰全科医生无应答的原因。方法：在PEM中，每位患者在首次开药后约6个月将问卷调查表发给开处方的全科医生，要求提供自治疗开始以来记录在患者笔记中的临床事件的详细信息。那些没有回答的人被发送了第二份问卷，包括问号，以阐明未回答的原因。结果：总共21.3％（3088/14502）的第二个发送表单被返回。共有1747个复选框响应。导致未回复的最常见原因是“我太忙”（31.2％），其次是“未付款”（13.4％）。参与另一项研究仅占3.4％。结论：并发上市后监督研究不是一个重要因素。全科医生的工作量似乎产生了更大的影响。虽然研究仍是一项非核心活动，并且没有收到任何报酬，但参与人数可能会下降。如果要继续参与，研究人员需要找到使全科医生受益的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号